Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not listed Phase 2 Interventional

A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma

ClinicalTrials.gov ID: NCT00931840

Public ClinicalTrials.gov record NCT00931840. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 27, 2026, 4:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 2, multicenter, multiple-arm, open-label study to evaluate the efficacy, safety, and tolerability of EZN-2208. EZN-2208 will be administered as a single agent in patients with K-RAS mutations in the tumors. Patients with wild type K-RAS in tumors will be randomized to EZN-2208 + cetuximab or to standard of care (Camptosar® + cetuximab), patients must have failed regimens containing irinotecan (Camptosar®, CPT-11), oxaliplatin (Eloxatin®), and fluoropyrimidine. After discontinuation of study treatment, patients will receive care as considered appropriate by the investigator. Patients will continue to be followed for disease progression, subsequent anticancer therapy, and survival.

Study identification

NCT ID
NCT00931840
Recruitment status
Not listed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Enzon Pharmaceuticals, Inc.
Industry
Enrollment
220 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2009
Primary completion
Sep 30, 2011
Completion
Dec 31, 2011
Last update posted
Sep 19, 2011

2009 – 2012

United States locations

U.S. sites
35
U.S. states
16
U.S. cities
33
Facility City State ZIP Site status
Location #033 Tucson Arizona 85724-5024 —
Location# 042 Alhambra California 91801 —
Location # 043 Bakersfield California 93309 —
Location# 044 Fullerton California 92835 —
Location# 019 La Jolla California 92093-0698 —
Location# 046 Long Beach California 90813 —
Location# 053 Los Angeles California 90095 —
Location# 051 Northridge California 91235 —
Location# 045 Pomona California 91767 —
Location # 048 Santa Barbara California 93105 —
Location # 049 Santa Barbara California 93105 —
Location# 052 Santa Maria California 93454 —
Location #027 Stanford California 94305 —
Location# 003 Newark Delaware 19718 —
Location# 047 Orlando Florida 32804 —
Location# 022 Port Saint Lucie Florida 34952 —
Location# 005 Marietta Georgia 30060 —
Location# 009 Chicago Illinois 60611-2927 —
Location #050 Terre Haute Indiana 47802 —
Location# 029 Worcester Massachusetts 01655 —
Location #031 Lebanon New Hampshire 03756 —
Location # 030 Buffalo New York 14263 —
Location# 035 New York New York 10003 —
Location# 002 New York New York 10016 —
Location# 007 The Bronx New York 10461 —
Location# 001 Chapel Hill North Carolina 27514 —
Location# 020 Goldsboro North Carolina 27534 —
Location# 024 Winston-Salem North Carolina 27103 —
Location# 008 Columbus Ohio 43210 —
Location# 037 Lancaster Pennsylvania 17605 —
Location# 018 Greenville South Carolina 29615 —
Location# 004 Memphis Tennessee 38138 —
Location #038 Houston Texas 77584 —
Location# 011 Lubbock Texas 79410 —
Location# 021 San Antonio Texas 78229 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00931840, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 19, 2011 · Synced Sep 27, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00931840 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →